• 1
    Privitera MD. Topiramate: a new antiepileptic drug. Ann Pharmacother 1997;31: 116473.
  • 2
    Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, 600-mg dosages. Neurology 1996;46: 168490.
  • 3
    Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, 1000-mg dosages. Neurology 1996;46: 167883.
  • 4
    Sachdeo RC, Glauser TA, Ritter RC, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 1999;52: 18827.
  • 5
    Biton V, Montouris GD, Ritter F. A study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999;52: 13307.
  • 6
    Tatum WO, French JA, Morris GL, et al. Postmarketing experience with topiramate and cognition. Epilepsia 2001;42: 113440.
  • 7
    Schmitz B. Psychiatric syndromes related to antiepileptic drugs. Epilepsia 1999;40(suppl 10):S6570.
  • 8
    Lhatoo SD, Wong ICK, Sander JWAS. Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy. Epilepsia 2000;41: 3341.
  • 9
    Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356: 12559.
  • 10
    Blumer D, Altshuler LL. Affective disorders. In: EngelJ, PedleyT, eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven, 1997: 208399.
  • 11
    Kellett MW, Smith DF, Stockton PA, et al. Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic. J Neurol Neurosurg Psychiatry 1999;66: 75963.
  • 12
    Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin and lamotrigine in healthy young adults. Neurology 1999;52: 3217.
  • 13
    Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000;41: 116778.
  • 14
    Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996;37(suppl 2):S1822.
  • 15
    Crawford P. An audit of topiramate use in a general neurology clinic. Seizure 1998;7: 20711.
  • 16
    Klufas A, Thompson D. Topiramate-induced depression. Am J Psychiatry 2001;158: 1736.
  • 17
    Kanner AM, Faught E, French JA, et al. Psychiatric adverse events caused by topiramate and lamotrigine: a postmarketing prevalence and risk factor study [Abstract]. Epilepsia 2000;41(suppl 7):169.
  • 18
    Trimble MR, Rusch N, Betts T, et al. Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables. Seizure 2000;9: 24954.
  • 19
    Trimble MR. The psychoses of epilepsy. New York: Raven Press, 1991.
  • 20
    Sander JWAS, Hart YM, Trimble MR, et al. Vigabatrin and psychosis. J Neurol Neurosurg Psychiatry 1991;54: 4359.
  • 21
    Thomas L, Trimble M, Schmitz B, et al. Vigabatrin and behaviour disorders: retrospective survey. Epilepsy Res 1996;25: 217.
  • 22
    Gerber PE, Hamiwka L, Connolly MB, et al. Factors associated with behavioural and cognitive abnormalities in children receiving topiramate. Pediatr Neurol 2000;22: 2003.
  • 23
    Kelly K, Stephen LJ, Sills GJ, et al. Topiramate in patients with learning disability and refractory epilepsy. Epilepsia 2002;43: 399402.